How BrightHeart uses Meta’s DINOv2 to transform fetal heart screenings

For children born with congenital heart defects (CHDs), early diagnosis before birth is essential to ensure that the baby will receive optimized care after delivery for the best possible outcome. However, only 34% of congenital heart defects are detected prenatally. BrightHeart, a medical technology company based in Paris, has made it their mission to improve fetal heart screening. The company has created AI-powered medical software with the support of Meta’s DINOv2 model to help clinicians identify or rule out signs suggestive of congenital heart defects faster and more accurately, with the aim of improving the prognosis for affected children.